News
PriMHE Lecture: Relative Effectiveness and the Impact on Drug Development
28 May 2015
OHE’s Adrian Towse will give a lecture at the Medical University of Vienna on relative effectiveness and the impact on drug development.
Do Financial Incentives Trump Clinical Guidance? Hip Replacement Treatment in England and Scotland
19 May 2015
This post provides an overview of Dr Irene Papanicolas and Professor Alistair McGuire’s OHE Lunchtime Seminar on the effect of financial incentives on hip replacement in…
OHE Lunchtime Seminar on 11 June 2015: The Economics of Elevated Hospital Mortality at Weekends
14 May 2015
Professor Sutton will explore whether the introduction of comprehensive seven day hospital services in the NHS is likely to reduce weekend deaths and be a cost-effective…
OHE at ISPOR Philadelphia Part 2: Risk Sharing, Medical Breakthroughs, Early Access and Drug Development Costs
12 May 2015
This post is the second of a two part summary of OHE’s scheduled activity at ISPOR Philadelphia 2015.
OHE at ISPOR Philadelphia Part 1: MCDA, Utility Functions and Big Data
7 May 2015
This post is the first of a two part summary of OHE’s scheduled activity at ISPOR Philadelphia 2015.
OHE’s Professor Nancy Devlin and Koonal Shah Join the EuroQol Research Foundation’s Valuation Working Group
5 May 2015
OHE’s Professor Nancy Devlin and Koonal Shah have both been appointed to serve on the Valuation Working Group of the EuroQol Research Foundation.
international Decision Support Initiative (iDSI): Mapping of Priority-setting in Health in 17 Low and Middle Income Countries Across Asia, Latin America and Africa
22 April 2015
This mapping of priority-setting considers factors such as existence of HTA institutions and commitment to UHC (Brazil, Chile, Colombia, Mexico, Uruguay, Ghana, Kenya, Malawi, South Africa,…
OHE Publishes in the Journal of Comparative Effectiveness Research: Future Expectations of Evidence of Relative Effectiveness in Europe and Comparative Effectiveness in the USA in 2020
15 April 2015
Articles co-authored by Adrian Towse, Martina Garau, Donna Messner, and Penny Mohr exploring future expectations of drug relative effectiveness in Europe and comparative effectiveness in the…
New Business Models for Antibiotics. What Can We Learn from Other Industries?
7 April 2015
The business model for antibiotics is broken. We looked at other industries facing conceptually similar challenges – particularly when the incentive for R&D is delinked from…